Related Experiment Video

Updated: Jul 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K

Editorial: Advancing precision therapies in glioblastoma

Theophilos Tzaridis1, Marike Broekman2, Konstantinos Gousias3,4,5

  • 1Cancer Genome and Epigenetics Program, NCI-Designated Cancer Center, Sanford Burnham, Prebys Medical Discovery Institute, La Jolla, CA, United States.

Frontiers in Oncology
|October 13, 2025
PubMed
Abstract

No abstract available in PubMed .

Keywords:
biomarkersblood-brain barrierdrug deliveryglioblastomatargeted therapytherapy

More Related Videos

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.1K

Related Experiment Videos

Last Updated: Jul 19, 2026

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.8K
The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma
08:00

The Clinical Application of Tumor Treating Fields Therapy in Glioblastoma

Published on: April 16, 2019

19.1K
Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment
09:02

Author Spotlight: Innovative Cancer Therapies with Iron Oxide Nanoparticles for Glioblastoma Treatment

Published on: September 27, 2024

3.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Articles linked to this work by shared authors, journal, and citation graph.

CD155 regulates tumor growth and susceptibility to T cell mediated killing in diffuse midline glioma.

Neuro-oncology·2026

Immune cell imaging in the glioma microenvironment.

Brain research·2026

Ethical aspects of waiting lists in neurosurgery.

Acta neurochirurgica·2026

Systematic design of combination therapy by targeting master regulators of coexisting diffuse midline glioma cell states.

Nature genetics·2026

The Ki-67 proliferation index and recurrence risk of intracranial meningioma: a multicenter, retrospective cohort study of 5,050 patients.

Acta neurochirurgica·2026

ONC206 demonstrates potent antitumorigenic activity and is a potential novel therapeutic strategy for high-risk medulloblastoma.

Neuro-oncology·2026

Beyond anatomy: deciphering metastasis to enhance diagnosis and treatment in head and neck carcinoma of unknown primary.

Frontiers in oncology·2026

Circulating tumor DNA in colorectal cancer: assay selection, clinical applications, and practical integration for gastroenterologists.

Frontiers in oncology·2026

Artificial intelligence standardizes CT-based body composition analysis in breast cacer to address methodological heterogeneity.

Frontiers in oncology·2026

Case Report: squamous transformation after long-term osimertinib in EGFR-mutant lung adenocarcinoma with retained EGFR/TP53 alterations.

Frontiers in oncology·2026

Correction: 18F-FDG PET/CT for predicting major pathological response to neoadjuvant therapy in non-small cell lung cancer: a meta-analysis.

Frontiers in oncology·2026

Cellular variant focal segmental glomerulosclerosis during trastuzumab emtansine treatment in HER2-positive breast cancer: a case report.

Frontiers in oncology·2026

Trojan mast cells: repurposing allergy for targeted oncolytic delivery.

Trends in pharmacological sciences·2026

Remote photobiomodulation: A systemic approach to neuroprotection.

International review of neurobiology·2026

Towards macrophage-oriented Antituberculosis therapy: nanohydrogel and liposomal delivery of rifampicin-berberine Co-nanocrystals for enhanced intracellular Antituberculosis activity.

European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V·2026

Oligomerized receptor binding domain blocks pan-sarbecovirus infection via enhanced avidity to host receptor.

Antiviral research·2026

A first realization of reinforcement learning-based closed-loop EEG-TMS.

NeuroImage·2026

FcBP-HFQ lipid-mediated trastuzumab modification of mRNA-loaded lipid nanoparticles enhances delivery to HER2-expressing cancer cells.

European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us